NEWS | alsv

Companies in the News

eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion

Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant...

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study

10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike...

Generate:Biomedicines Announces Close of $273M Series C Financing

Funding will advance pipeline of 17 existing programs and approximately 10 new starts annually Company has raised nearly $700 million in...

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc....

EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results

Data Presented at Late-Breaking Session at Heart Rhythm Society 2023: Paves Way for Premarket Approval Application for Federal Drug...

Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement

Multi-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways...

Sana Biotechnology Announces Preclinical Data Published in Nature Communications

Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic...

Ring Therapeutics Raises $86.5M in Series C Funding to Create Next Generation Programmable Medicines

Ring raised a total of $86.5 million from new and returning investors, validating its unique approach to creating next-generation...

Aera Therapeutics Launches with $193 M for the Next Generation of Transformative Genetic Medicines

Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range...